AML: options after venetoclax-based regimen failure

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, outlines the options for acute myeloid leukemia (AML) patients that fail venetoclax-based regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.